期刊
ANTIVIRAL RESEARCH
卷 183, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2020.104879
关键词
Adenovirus; Synthetic stigamastane; Antiviral; Antiinflammatory
资金
- Agencia Nacional de Promocion Cientffica y Tecnologica (ANPCyT) [PICT 0914, PICT 2010-0853]
- CONICET [PIP 1007]
- Universidad de Buenos Aires (UBACyT) [20020100100522]
- Instituto Massone S.A., Argentina
Although human adenovirus (ADV) infections are mild and self-limited in immunocompetent individuals, they can be severe and life-threatening in immunocompromised patients. Despite their significant clinical impact, there are not currently approved antiviral therapies for ADV infections. On the other hand, in some cases, the immune response induced by ADV infection can cause tissue damage. Even more, in the case of adenovirus vectors used in gene therapy, host immunity generally antagonize viral efficacy. Therefore, the need for searching an effective and safe therapy is increasing. In this work, we describe the antiadenoviral activity of the synthetic stigmastane (225, 235)-22,23-dihydroxystigmast-4-en-3-one (Compound 1) with already reported antiviral and antiinflammatory activities against other viruses of clinical importance. Compound 1 displayed no virucidal activity and did not affect ADV entry to the cells. The compound inhibited viral replication and it also reduced cytokine secretion in epithelial and inflammatory infected cells. Thus, Compound 1 would be a promissory drug potentially useful against adenoviral infections as well as an adjuvant of adenoviral vectors in gene therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据